4.6 Article

Recent advances in the histo-molecular pathology of human prion disease

Journal

BRAIN PATHOLOGY
Volume 29, Issue 2, Pages 278-300

Publisher

WILEY
DOI: 10.1111/bpa.12695

Keywords

amyloidosis; Creutzfeldt-Jakob disease; fatal insomnia; Gerstmann-Straussler-Scheinker disease; human prions; neurodegenerative dementia; prion strains

Ask authors/readers for more resources

Prion diseases are progressive neurodegenerative disorders affecting humans and other mammalian species. The term prion, originally put forward to propose the concept that a protein could be infectious, refers to PrPSc, a misfolded isoform of the cellular prion protein (PrPC) that represents the pathogenetic hallmark of these disorders. The discovery that other proteins characterized by misfolding and seeded aggregation can spread from cell to cell, similarly to PrPSc, has increased interest in prion diseases. Among neurodegenerative disorders, however, prion diseases distinguish themselves for the broader phenotypic spectrum, the fastest disease progression and the existence of infectious forms that can be transmitted through the exposure to diseased tissues via ingestion, injection or transplantation. The main clinicopathological phenotypes of human prion disease include Creutzfeldt-Jakob disease, by far the most common, fatal insomnia, variably protease-sensitive prionopathy, and Gerstmann-Straussler-Scheinker disease. However, clinicopathological manifestations extend even beyond those predicted by this classification. Because of their transmissibility, the phenotypic diversity of prion diseases can also be propagated into syngenic hosts as prion strains with distinct characteristics, such as incubation period, pattern of PrPSc distribution and regional severity of histopathological changes in the brain. Increasing evidence indicates that different PrPSc conformers, forming distinct ordered aggregates, encipher the phenotypic variants related to prion strains. In this review, we summarize the most recent advances concerning the histo-molecular pathology of human prion disease focusing on the phenotypic spectrum of the disease including co-pathologies, the characterization of prion strains by experimental transmission and their correlation with the physicochemical properties of PrPSc aggregates.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Evaluation of the impact of CSF prion RT-QuIC and amended criteria on the clinical diagnosis of Creutzfeldt-Jakob disease: a 10-year study in Italy

Andrea Mastrangelo, Angela Mammana, Simone Baiardi, Dorina Tiple, Elisa Colaizzo, Marcello Rossi, Luana Vaianella, Barbara Polischi, Michele Equestre, Anna Poleggi, Sabina Capellari, Anna Ladogana, Piero Parchi

Summary: The introduction of the Real-Time Quaking-Induced Conversion assay has led to a revision of the diagnostic criteria for sporadic Creutzfeldt-Jakob disease. This study compares the diagnostic value of the old and amended criteria and explores different combinations of clinical variables and biomarker results. The results show that CSF RT-QuIC is highly sensitive and specific for diagnosing CJD, and the Q-CM criteria provide a high diagnostic value.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Defining the phenotypic spectrum of sporadic Creutzfeldt-Jakob disease MV2K: the kuru plaque type

Simone Baiardi, Angela Mammana, Sofia Dellavalle, Marcello Rossi, Veronica Redaelli, Elisa Colaizzo, Giuseppe Di Fede, Anna Ladogana, Sabina Capellari, Piero Parchi

Summary: The study systematically characterized the clinical and histo-molecular features of the MV2 subtype with kuru plaques in Creutzfeldt-Jakob disease. They evaluated the neurological histories, biomarkers, MRI and EEG results of 126 patients and found that the MV2K subtype has distinct features, including a longer disease duration, prominent cerebellar symptoms, and positive cerebrospinal fluid tests. The use of real-time quaking-induced conversion assay and brain diffusion-weighted MRI can improve early clinical diagnosis in most patients.

BRAIN (2023)

Article Clinical Neurology

Elevated plasma p-tau181 levels unrelated to Alzheimer's disease pathology in amyotrophic lateral sclerosis

Veria Vacchiano, Andrea Mastrangelo, Corrado Zenesini, Simone Baiardi, Patrizia Avoni, Barbara Polischi, Sabina Capellari, Fabrizio Salvi, Rocco Liguori, Piero Parchi

Summary: This study found that phosphorylated-tau181 (p-tau181), a specific marker of Alzheimer's disease pathology, was elevated in the plasma of patients with amyotrophic lateral sclerosis (ALS) but not in their cerebrospinal fluid (CSF). The study explored clinical/electrophysiological associations, prognostic value, and longitudinal trajectories of the biomarker.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Misfolded α-Synuclein Assessment in the Skin and CSF by RT-QuIC in Isolated REM Sleep Behavior Disorder

Alex Iranzo, Angela Mammana, Amaia Munoz-Lopetegi, Sofia Dellavalle, Gerard Maya, Marcello Rossi, Monica Serradell, Simone Baiardi, Aurora Arqueros, Corinne Quadalti, Andres Perissinotti, Edoardo Ruggeri, Joan Santamaria Cano, Carles Gaig, Piero Parchi

Summary: This study compares the ability of real-time quaking-induced conversion (RT-QuIC) assay to detect misfolded alpha-synuclein (AS) in the skin and cerebrospinal fluid (CSF) for the identification of patients with isolated REM sleep behavior disorder (IRBD). The results show that RT-QuIC detects AS in the skin and CSF with similar high sensitivity, specificity, and agreement, and can serve as a patient selection strategy for future neuroprotective trials targeting AS in IRBD.

NEUROLOGY (2023)

Article Biochemistry & Molecular Biology

Strain-Dependent Morphology of Reactive Astrocytes in Human- and Animal-Vole-Adapted Prions

Rosalia Bruno, Geraldina Riccardi, Floriana Iacobone, Flavia Chiarotti, Laura Pirisinu, Ilaria Vanni, Stefano Marcon, Claudia D'Agostino, Matteo Giovannelli, Piero Parchi, Umberto Agrimi, Romolo Nonno, Michele Angelo Di Bari

Summary: This study investigated the relationship between prion strains and astrocyte phenotype in six human- and animal-vole-adapted strains. The results showed that astrocyte morphology and astrocyte-associated PrPSc deposition varied depending on the strain, indicating strain-specific phenotypes of reactive astrocytes. Additionally, astrocyte-associated PrPSc deposition was observed in four out of six strains and correlated with astrocyte size.

BIOMOLECULES (2023)

Article Clinical Neurology

Rapidly progressive dementia due to intravascular lymphoma: A prion disease reference center experience

Giuseppe Mario Bentivenga, Simone Baiardi, Lorenzo Righini, Anna Ladogana, Sabina Capellari, Elena Sabattini, Piero Parchi

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Article Biochemistry & Molecular Biology

Amyloid-Beta Co-Pathology Is a Major Determinant of the Elevated Plasma GFAP Values in Amyotrophic Lateral Sclerosis

Andrea Mastrangelo, Veria Vacchiano, Corrado Zenesini, Edoardo Ruggeri, Simone Baiardi, Arianna Cherici, Patrizia Avoni, Barbara Polischi, Francesca Santoro, Sabina Capellari, Rocco Liguori, Piero Parchi

Summary: Recent studies have shown that ALS patients have higher levels of plasma GFAP compared to controls, and this marker is associated with cognitive decline. Plasma GFAP is an accurate biomarker for identifying Alzheimer's disease co-pathology in ALS, which can influence the cognitive phenotype.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Cognitive effects of Lewy body pathology in clinically unimpaired individuals

Sebastian Palmqvist, Marcello Rossi, Sara Hall, Corinne Quadalti, Niklas Mattsson-Carlgren, Sofia Dellavalle, Pontus Tideman, Joana B. Pereira, Maria H. Nilsson, Angela Mammana, Shorena Janelidze, Simone Baiardi, Erik Stomrud, Piero Parchi, Oskar Hansson

Summary: A long-term study reveals that Lewy body pathology in clinically unimpaired individuals is associated with worse smell and cognitive functions, as well as predicts cognitive decline and progression to Parkinson's disease or dementia with Lewy bodies. The study also found that α-synuclein aggregates have negative effects on cognition and memory, while tau pathology has similar effects but less pronounced for β-amyloid. Participants with both Lewy body and Alzheimer's disease pathology exhibited faster cognitive decline. These findings have implications for prognosis, recruitment, and outcome measures in preclinical Lewy body disease and early Alzheimer's disease trials.

NATURE MEDICINE (2023)

Article Biochemistry & Molecular Biology

Clinical effects of Lewy body pathology in cognitively impaired individuals

Corinne Quadalti, Sebastian Palmqvist, Sara Hall, Marcello Rossi, Angela Mammana, Shorena Janelidze, Sofia Dellavalle, Niklas Mattsson-Carlgren, Simone Baiardi, Erik Stomrud, Oskar Hansson, Piero Parchi

Summary: Prospective and longitudinal analyses of patients with cognitive impairment revealed that the in vivo detection of Lewy body pathology is independently associated with hallucinations, worse attention/executive, visuospatial and motor function, and predicted future cognitive decline. LB pathology has clinical effects in patients with cognitive impairment, especially in those coexisting with AD pathology. LB pathology is associated with faster cognitive decline, regardless of AD pathology and cognitive stage, which suggests that LB status is a better predictor for clinical trajectories than AD biomarkers and clinical diagnosis.

NATURE MEDICINE (2023)

Article Cell Biology

DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease

Joana B. Pereira, Atul Kumar, Sara Hall, Sebastian Palmqvist, Erik Stomrud, Divya Bali, Piero Parchi, Niklas Mattsson-Carlgren, Shorena Janelidze, Oskar Hansson

Summary: Using DOPA decarboxylase (DDC) levels in cerebrospinal fluid and plasma, patients with Lewy body disease (LBD) and atypical Parkinsonian disorders can be accurately identified and predicted, even during the preclinical stages.

NATURE AGING (2023)

No Data Available